All In Biotech

Drug Trial Radar · NCT02631551

Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)

A Double-Blind, Randomized, Parallel-Group, Comparative Study to Evaluate the Efficacy, Safety and Tolerability of a Fixed Dose Combination GSP 301 Nasal Spray (NS) Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Comparators) in Subjects (Aged 12 Years and Older) With Seasonal Allergic Rhinitis (SAR)

Last checked: Nov 19, 2026Latest source record: Sep 25, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,180 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,180

Actual

Start

Mar 2016

Primary completion

Jul 2016

Study completion Jul 2016

Sponsor

Lead sponsor
Glenmark Specialty S.A.Industry
Sponsor type
Industry
First posted
Dec 16, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study to evaluate the efficacy and safety of GSP 301 NS compared to placebo NS and to individual monotherapies (comparators) as well as the efficacy of these monotherapies (comparators) versus placebo NS over 14 days of study treatment

Conditions

  • Seasonal Allergic Rhinitis

Interventions

  • GSP 301 NSDrug

    FDC of olopatadine HCl and mometasone furoate: 2 sprays in each nostril twice daily for 14 days

  • Olopatadine HCl NSDrug

    2 sprays in each nostril twice daily for 14 days

  • Mometasone furoate NSDrug

    2 sprays in each nostril twice daily for 14 days

  • GSP 301 Placebo NSDrug

    2 sprays in each nostril twice daily for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Average AM and PM Subject-reported 12-hour Reflective Total Nasal Symptoms Score (rTNSS) From Baseline to End of Treatment.Time frame: 14 days

Locations

37 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site 20

    Mission Viejo, California

  • Investigational Site 31

    San Diego, California

  • Investigational Site 29

    San Jose, California

  • Investigational Site 25

    Centennial, Colorado

  • Investigational Site 22

    Colorado Springs, Colorado

  • Investigational Site 10

    Jupiter, Florida

  • Investigational Site 30

    Miami, Florida

  • Investigational Site 37

    Marietta, Georgia

  • Investigational Site 15

    Stockbridge, Georgia

  • Investigational Site 23

    Stockbridge, Georgia

  • Investigational Site 11

    Louisville, Kentucky

  • Investigational Site 14

    Baltimore, Maryland

  • Investigational Site 33

    Wheaton, Maryland

  • Investigational Site 26

    Ypsilanti, Michigan

  • Investigational Site 19

    Minneapolis, Minnesota

  • Investigational Site 21

    St Louis, Missouri

  • Investigational Site 16

    Bellevue, Nebraska

  • Investigational Site 12

    Skillman, New Jersey

  • Investigational Site 36

    Rochester, New York

  • Investigational Site 18

    Raleigh, North Carolina

  • Investigational Site 27

    Cincinnati, Ohio

  • Investigational Site 34

    Middleburg Heights, Ohio

  • Investigational Site 32

    Medford, Oregon

  • Investigational Site 35

    Portland, Oregon

  • Investigational Site 13

    Orangeburg, South Carolina

  • Investigational Site 17

    Spartanburg, South Carolina

  • Investigational Site 3

    Austin, Texas

  • Investigational Site 5

    Austin, Texas

  • Investigational Site 8

    Austin, Texas

  • Investigational Site 1

    Kerrville, Texas

  • Investigational Site 7

    New Braunfels, Texas

  • Investigational Site 2

    San Antonio, Texas

  • Investigational Site 4

    San Antonio, Texas

  • Investigational Site 6

    San Antonio, Texas

  • Investigational Site 9

    San Antonio, Texas

  • Investigational Site 28

    Waco, Texas

  • Investigational Site 24

    Draper, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.